<DOC>
	<DOC>NCT02213263</DOC>
	<brief_summary>This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU.</brief_summary>
	<brief_title>A Study Of PF-05280586 (Rituximab-Pfizer) Or MabTheraÂ® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Confirmed diagnosis of low tumor burden, CD20positive follicular lymphoma Ann Arbor Stage II, III, or IV Not a candidate for treatment with rituximab as a singleagent Evidence of transformation to a high grade or diffuse large Bcell lymphoma Any previous systemic therapy for Bcell NHL, including chemotherapy, immunotherapy, or steroids Any prior treatment with rituximab Active, uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>rituximab</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>Non-Hodgkin lymphoma</keyword>
	<keyword>Non-Hodgkin's lymphoma</keyword>
</DOC>